Jump to Section
What to Know: ASCO's Guideline on White Blood Cell Growth FactorsIntroduction January 25, 2008: Special Announcement on sargramostim (Leukine): Patients and doctors need to be aware that there has been a voluntary market suspension of the current liquid formulation of this drug because of an upward trend in spontaneous reports of adverse reactions, including syncope (fainting). The lyophilized (freeze-dried) form of the drug is not affected. See the U.S. Food and Drug Administration (FDA) web site at www.fda.gov for more information. Introduction To help doctors give their patients the best possible care, the American Society of Clinical Oncology (ASCO) developed recommendations for the use of white blood cell growth factors. This guide for patients is based on ASCO’s recommendations. Key Messages
Last Updated: October 05, 2010 | Next > |